Showing results (1501-1510 of 10,079) with videos related to
Sort By:
Pageof 1,008
Current Pharmaceutical Design|November 28, 2012
Targeting the ubiquitin proteasome system: beyond proteasome inhibitionWendy Xolalpa, Patricia Perez-Galan, Manuel S Rodríguez, et al.Current Pharmaceutical Design|December 25, 2012
Drug design for protein kinases and phosphatases: flexible-receptor docking, binding affinity and specificity, and drug-binding kineticsChung F Wong, Sneha BairyCurrent Pharmaceutical Design|December 25, 2012
Advances in binding free energies calculations: QM/MM-based free energy perturbation method for drug designR S Rathore, M Sumakanth, M Siva Reddy, et al.Current Pharmaceutical Design|December 29, 2012
Protecting the heart: biological targets and clinical strategiesAlberto R De Caterina, Florim Cuculi, Adrian P Banning, et al.Current Pharmaceutical Design|January 12, 2013
Long-term etanercept therapy favors weight gain and ameliorates cachexia in rheumatoid arthritis patients: roles of gut hormones and leptinChih-Yen Chen, Chang-Youh Tsai, Pui-Ching Lee, et al.Current Pharmaceutical Design|December 12, 2012
Sevoflurane in intraoperative and postoperative cardiac surgery patients. Our experience in intensive care unit with sevoflurane sedationJose Luis Guerrero Orriach, M Ramirez Aliaga, Manuel Galan Ortega, et al.Current Pharmaceutical Design|December 12, 2012
Clopidogrel, aspirin and proton pump inhibition after percutaneous valve implants: an updateMelissa FusariCurrent Pharmaceutical Design|January 3, 2013
Microalbuminuria: a neglected cardiovascular risk factor in non-diabetic individuals?Eirini Lioudaki, Matilda Florentin, Emmanuel S Ganotakis, et al.Current Pharmaceutical Design|January 3, 2013
Statin therapy and new-onset diabetes: molecular mechanisms and clinical relevanceMaciej Banach, Malgorzata Malodobra-Mazur, Anna Gluba, et al.Current Pharmaceutical Design|January 3, 2013
Uric acid and diabetes: Is there a link?Niki Katsiki, Nikolaos Papanas, Vivian A Fonseca, et al.Pageof 1,008